Drug · DIN 02440970
FETZIMA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 11, 2023; first marketed November 19, 2015.
- Drug Identification Number (DIN)
- 02440970
- Company (DIN owner)
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Capsule (Extended-Release)
- Route
- Oral
- Therapeutic class (ATC)
- Levomilnacipran N06AX28
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) | 20 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 29, 2022: NOC 28846New Drug Submission (NDS) · Administrative: Merger/Buy-out
- October 13, 2016: NOC 18566New Drug Submission (NDS) · Manufacturer name change
- May 8, 2015: NOC 16888New Drug Submission (NDS)
Other DINs named FETZIMA
- DIN 02440989 · Marketed
- DIN 02440997 · Marketed
- DIN 02441004 · Marketed